| 摘要 |
<p>The blood collection, processing and transfer by separation of discrete components containing additional citrate in one or other of collection or processing bag provides for enhanced yield impurity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products, which include fibrin glue, is achieved.</p> |
